We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of antiandrogen withdrawal syndrome in castration‐resistant prostate cancer patients treated with abiraterone or enzalutamide.
- Authors
Shiota, Masaki; Machidori, Asako; Abe, Tatsuro; Monji, Keisuke; Kashiwagi, Eiji; Takeuchi, Ario; Takahashi, Ryosuke; Inokuchi, Junichi; Yokomizo, Akira; Naito, Seiji; Eto, Masatoshi
- Abstract
Objectives: To assess the impact of antiandrogen withdrawal syndrome after bicalutamide withdrawal in castration‐resistant prostate cancer patients treated with androgen receptor‐axis targeted agents. Methods: The study cohort comprised 94 patients treated with abiraterone (n = 34) or enzalutamide (n = 60) as a first‐line androgen receptor‐axis targeted agent for castration‐resistant prostate cancer despite combined androgen blockade by castration with bicalutamide as the first‐line therapy. The association between clinicopathological factors (including antiandrogen withdrawal syndrome) and therapeutic outcome after using abiraterone and enzalutamide was investigated. Results: The decline in the prostate‐specific antigen level after use of abiraterone or enzalutamide was comparable between patients with and without antiandrogen withdrawal syndrome. Antiandrogen withdrawal syndrome (hazard ratio 3.84, 95% confidence interval 1.29–11.45; P = 0.016) was associated with a higher risk of progression on multivariate analysis, but not all‐cause death after abiraterone use. Progression‐free survival and overall survival after enzalutamide use did not differ between patients with and without antiandrogen withdrawal syndrome. Conclusions: The present data suggest a modest therapeutic efficacy of abiraterone in castration‐resistant prostate cancer patients with anti‐androgen withdrawal syndrome after bicalutamide withdrawal.
- Subjects
CASTRATION-resistant prostate cancer; PROSTATE cancer patients; PROSTATE-specific antigen; TREATMENT effectiveness; SYNDROMES
- Publication
International Journal of Urology, 2020, Vol 27, Issue 12, p1109
- ISSN
0919-8172
- Publication type
Article
- DOI
10.1111/iju.14366